Danish biotechnology company Genmab has announced top line results from the Phase III EPCORE DLBCL-1 trial, highlighting improved progression-free survival (PFS) for its subcutaneous bispecific ...

Epkinly monotherapy significantly improved progression-free survival in relapsed/refractory DLBCL patients, reducing cancer ...

Company Announcement Based on the topline results from the EPCORE® DLBCL-1 trial, Genmab will engage global regulatory authorities to discuss ...

Genmab (GMAB) on Friday announced that its bispecific antibody epcoritamab, marketed as Epkinly in partnership with AbbVie ...

Despite the late-stage miss, analysts maintained confidence in the Epkinly program, with Truist Securities saying the result ...

Topline results show that epcoritamab, a T-cell engaging bispecific antibody administered subcutaneously, demonstrated an improvement in PFS in patients receiving epcoritamab monotherapy (HR, 0.74; 95 ...

Friday afternoon, the company and its partner Genmab shared word that the phase 3 Epcore DLBCL-1 trial missed on its primary ...

Abdominal/gastrointestinal complaints are the most prevalent initial symptoms in DLBCL, reported by 26% of patients. Peripheral lymphadenopathy and testicular tumors are associated with low-risk ...

Incyte Announces Positive Topline Results from Pivotal Study of Tafasitamab (Monjuvi®/Minjuvi®) as a First-line Treatment for DLBCL ...

—This large, population-based study of patients with PP-DLBCL assessed prognostic factors and confirmed that certain common therapeutic interventions can modify disease progression. Being age 65 years ...

AbbVie (NYSE: ABBV) today announced topline results from the Phase 3 EPCORE® DLBCL-1 trial evaluating epcoritamab, a T-cell engaging bispecific antibody administered subcutaneously, compared to ...